Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25433533 | 1.00 | GRM5 (0.42) | GRM5POLBESR1RIPK1ALDH1A1 | |
| SCHEMBL25428874 | 0.89 | GRM5 (0.40) | GRM5RIPK1ALDH1A1 | |
| SCHEMBL25428870 | 0.89 | GRM5 (0.40) | GRM5RIPK1ALDH1A1 | |
| SCHEMBL26645071 | 0.82 | GRM5 (0.42) | GRM5RIPK1PDK1PDK2 | |
| SCHEMBL25431171 | 0.79 | GRM5 (0.46) | GRM5RIPK1PDK1PDK2 | |
| SCHEMBL25431176 | 0.79 | GRM5 (0.46) | GRM5RIPK1PDK1PDK2 | |
| SCHEMBL30519647 | 0.73 | RIPK1 (0.51) | GRM5RIPK1PDK1PDK2 | |
| SCHEMBL26025548 | 0.72 | SMARCA2 (0.38) | GRM5 | |
| SCHEMBL26025547 | 0.71 | NR1H2 (0.46) | GRM5ALDH1A1 | |
| SCHEMBL25412001 | 0.69 | GRM5 (0.46) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |